6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03412513
(ClinicalTrials.gov)
July 17, 201721/1/2018Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseMirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled TrialOveractive Bladder;Parkinson DiseaseDrug: Mirabegron;Drug: PlaceboSeoul National University HospitalNULLUnknown status40 Years80 YearsAll144Phase 4Korea, Republic of
2NCT02536976
(ClinicalTrials.gov)
December 201528/8/2015Mirabegron in Parkinson Disease and Impaired CognitionA Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired CognitionParkinson Disease;Overactive Bladder;Impaired CognitionDrug: mirabegron;Drug: PlaceboHealthPartners InstituteNULLCompleted25 Years80 YearsAll7Phase 4United States
3NCT02092181
(ClinicalTrials.gov)
March 20147/3/2014A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)Parkinsons DiseaseDrug: Mirabegron;Drug: PlaceboDaniel Burdick, MDAstellas Pharma US, Inc.Completed30 Years85 YearsAll30Phase 4United States